Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aztreonam-avibactam versus best available therapy in pediatric serious gram-negative infections
2022-501575-12-00Phase 2Authorised
- Sponsor
- Pfizer
- Start
- Apr 2023
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 2, randomised, single-blind trial of aztreonam + avibactam in Intra-abdominal infection (IAI), complicated urinary tract infection (cUTI), bloodstream infection (BSI) and 4 more (2 arms), sponsored by Pfizer. Primary endpoints: Pharmacokinetic parameters of aztreonam and avibactam, Plasma concentrations of aztreonam and avibactam and 3 more. Planned start Apr 2023; status: authorised.
02
Drugs
aztreonam + avibactam
03
Conditions
Intra-abdominal infection (IAI)complicated urinary tract infection (cUTI)bloodstream infection (BSI)hospital-acquired pneumonia (HAP)ventilator-associated pneumonia (VAP)
Beyond the preview
Go deeper on 2022-501575-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501575-12-00.